Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
afatinib, AstraZeneca, beginning, Boehringer, Bristol, Carlo, concept, consecutive, convertible, dacomitinib, deducting, doubt, DSMB, Erbitux, evofosfamide, expedited, fast, faster, hallmark, head, Ingelheim, kinase, Monte, neck, nivolumab, NSCLC, payable, pembrolizumab, Pfizer, post, preliminary, reformulate, simulation, Society, Squibb, stability, stable, substance, synthesize, TKI, trademark, tyrosine, unchanged, underwriting, unmet, unstable
Removed:
abnormally, antiangiogenic, anticancer, bearing, bevacizumab, bone, carcinoma, chemotherapeutic, concentration, detain, digit, double, escalation, ESPP, expired, explore, gastrointestinal, hepatocellular, investigating, marrow, melanoma, monotherapy, neuroendocrine, oxygen, RCC, recurrent, renal, seize, showing, sorafenib, staffing, stroma, sunitinib, Vice
Filing tables
Filing exhibits
Related press release
MTEM similar filings
Filing view
External links